Page last updated: 2024-08-21

fluorobenzenes and Cardiovascular Diseases

fluorobenzenes has been researched along with Cardiovascular Diseases in 246 studies

Research

Studies (246)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.41)18.7374
1990's0 (0.00)18.2507
2000's113 (45.93)29.6817
2010's131 (53.25)24.3611
2020's1 (0.41)2.80

Authors

AuthorsStudies
Bots, ML; Chen, Y; Fu, L; Hu, B; Hu, H; Karlson, BW; Li, H; Li, X; Li, Z; Meng, X; Nie, Z; Wang, Y; Wei, D; Zhao, B; Zheng, H1
Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y1
Boekholdt, SM; Kastelein, JJ; Khaw, KT; Rana, JS; Sondermeijer, BM; Wareham, NJ1
Barter, PJ; Chapman, MJ; Giral, P1
Elisaf, M; Kei, A; Liberopoulos, E; Rizzo, M; Tellis, K; Tselepis, A1
Postmus, I; Trompet, S; Wouter Jukema, J1
Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK2
Kang, HC; Kim, CM; Kim, YS; Lee, JA; Lee, SY; Oh, HJ; Park, KC; Sin, DH; Sunwoo, S; Yang, YJ; Yu, BY1
Khanna, D; Mahalwar, R1
Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR1
Barratt, BJ; Chasman, DI; Danik, JS; MacFadyen, JG; Nyberg, F; Ridker, PM1
Bots, ML; de Korte, C; den Ruijter, HM; Groenewegen, KA; Lind, L; Peters, SA1
Burns, KM; Carlson, DM; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Weinstein, DL; Williams, LA1
Reiner, Ž; Tedeschi-Reiner, E1
Glynn, RJ; Mora, S; Ridker, PM1
Bae, JH; Bae, JW; Cha, MJ; Chae, IH; Cho, MC; Kim, HS; Kwon, TG; Lee, SP; Rha, SW; Suh, JW1
Caulfield, MP; Everett, BM; Hantash, FM; Khera, AV; Mora, S; Ridker, PM; Wohlgemuth, J2
Debanne, SM; Eckard, AR; Funderburg, NT; Jiang, Y; McComsey, GA1
Dubé, MP1
Andy Schuetz, C; Folse, H; Gandhi, S; Rengarajan, B; Sternhufvud, C1
Ridker, PM; van der Graaf, Y; van der Leeuw, J; Visseren, FL1
Kronenberg, F1
Kakuda, H; Matoba, M; Nagao, S; Nakatoh, H; Takekoshi, N1
Berger, H; Englert, H; Grittner, U; Katus, HA; Muckelbauer, R; Müller-Nordhorn, J; Prugger, C; Sonntag, F; Völler, H; Wegscheider, K; Willich, SN1
Toth, PP1
Ashton, V; Marrett, E; Neff, D; Ramey, DR; Tershakovec, AM; Zhang, NJ; Zhang, Q; Zhao, C1
Daida, H; Hata, M; Kaku, K; Kawamori, R; Kishimoto, J; Kurabayashi, M; Masuda, I; Nohara, R; Sakuma, I; Yamazaki, T; Yokoi, H; Yoshida, M1
Bays, HE; Colhoun, HM; Donahue, S; Du, Y; Hanotin, C; Jones, PH; Robinson, JG1
Chen, J; Li, P; Liang, X; Lin, Z; Mo, Y; Wang, Z; Xie, W1
Chapman, MJ; Giral, P; Simon, D1
Debanne, SM; Erlandson, KM; Jiang, Y; McComsey, GA1
Duncan, BB; Polanczyk, CA; Restelatto, LM; Ribeiro, RA; Stella, SF; Vieira, JL; Ziegelmann, PK1
Adams, SP; Sekhon, SS; Wright, JM1
Ban, MR; Hegele, RA; Ibrahim, C1
Debanne, S; Dirajlal-Fargo, S; Hileman, CO; Jiang, Y; Kinley, B; Longenecker, CT; McComsey, GA1
Laufs, U1
Bredie, SJ; Kramers, C; Lobo, CM; van der Vlugt, MJ; Willemsen, AE1
Drapkina, OM; Eliashevich, SO1
Hu, YZ; Wu, YX; Yang, Y1
Eaton Md, CB1
Erdmann, E; Hoppe, UC1
Kapur, NK; Musunuru, K1
Barillà, F; Donato, L; Petrini, N; Pulcinelli, FM; Riondino, S; Tanzilli, G; Torromeo, C1
Nicholls, SJ1
Kastelein, JJ; Marck, R; Meuwese, MC; Mooij, HL; Nieuwdorp, M; Stroes, ES; van Lith, B; Vink, H1
Hlatky, MA1
Danielson, E; Fonseca, FA; Genest, J; Glynn, RJ; Gotto, AM; Kastelein, JJ; Koenig, W; Libby, P; Lorenzatti, AJ; MacFadyen, JG; Nordestgaard, BG; Ridker, PM; Shepherd, J; Willerson, JT3
Couzin, J1
Koenig, W1
Glynn, RJ; MacFadyen, JG; Ridker, PM1
Mitka, M2
Parhofer, K1
Einecke, D1
Gagne, JJ; Polinski, JM1
Riesen, WF1
Lüscher, TF1
Coradi, B1
Scheen, AJ1
Devaraj, S; Jialal, I1
Berneis, K; Kapur, NK; Rini, GB; Rizzo, M; Spinas, GA1
Bansilal, S; Fuster, V1
Nissen, SE1
Campion, EW; Kritek, P1
Gibbons, RJ1
Fugh-Berman, A1
Chan, PS; Hayward, RA; Nallamothu, BK1
Chan, ES; Mak, KH1
Jenny-Avital, ER1
Bucher, HC; Koller, MT; Steyerberg, EW1
Pierard, LA1
Davis, CE1
Lubsen, J1
Koopmans, RP1
Bredie, B1
Blumenthal, RS; Michos, ED1
Berneis, K; Rini, GB; Rizzo, M; Spinas, GA1
Després, JP1
Craig, JC; Strippoli, GF1
Bannister, K; Beutler, J; Chae, DW; Chevaile, A; Cobbe, SM; De Lima, JJ; Fellström, BC; Gottlow, M; Grönhagen-Riska, C; Holdaas, H; Jardine, AG; Johnsson, E; Lins, R; Mayer, G; McMahon, AW; Parving, HH; Remuzzi, G; Samuelsson, O; Schmieder, RE; Sci, D; Sonkodi, S; Süleymanlar, G; Tesar, V; Todorov, V; Tsakiris, D; Wiecek, A; Wüthrich, RP; Zannad, F1
Keba, E; Laks, T; Leiner, M; Merilind, E; Otter, K; Petersen, M; Reinmets, S; Sööt, T; Väli, S1
Bosch, J; Lonn, E; Yusuf, S1
Davidson, MH; Friedewald, VE; Ridker, PM; Roberts, WC; Willerson, JT1
Gentile, M; Marotta, G; Rubba, P1
Fabbri, G; Maggioni, AP1
Kones, R2
Narkiewicz, K1
Bell, DS; Carter, MD; Lavie, CJ; O'Keefe, JH1
Ridker, PM5
Gaspardone, A; Maseri, A1
Wheeler, DC1
Güleç, S1
Ganguli, A1
Danchin, N1
de Tena, JG1
Feeman, WE1
Bloom, JM1
Parra, D; Rosenstein, R1
Sniderman, AD1
Ruilope, LM; Segura, J1
Kassimatis, TI; Konstantinopoulos, PA1
de Oliveira, JM1
Watson, KE1
Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K1
Stewart, RA1
Plonk, WM1
Heintjes, EM; Herings, RM; Johansson, S; Penning-van Beest, FJ; Stalenhoef, AF1
Fonseca, FA; Izar, MC1
Jones, JK; Ming, EE; Motsko, SP; Russmann, S; Singh, VP; Vendiola, RM1
Bell, DS; O'Keefe, JH1
Katona, A; Márk, L1
Barrios, V; Escobar, C1
Amsterdam, EA; Kappagoda, CT1
Fricker, J1
Couzin-Frankel, J1
Blaha, MJ; Blumenthal, RS; Michos, ED; Narla, V1
Eren, M1
Barter, PJ; Brandrup-Wognsen, G; Nicholls, SJ; Palmer, M1
Allan, GM; McCormack, JP1
Blumenthal, R; Duvernoy, CS1
Macias, JF; Robles, NR1
Accad, M; Fred, HL1
Bajpai, A; Goyal, A; Sperling, L1
Glynn, RJ; Koenig, W; Nordestgaard, BG; Ridker, PM; Shepherd, J1
Ouyang, P; Zieman, SJ1
Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P1
Glynn, RJ; Ridker, PM2
Goldstein, MR; Mascitelli, L; Pezzetta, F1
Abramson, J; de Lorgeril, M; Dodin, S; Hamazaki, T; Kostucki, W; Okuyama, H; Pavy, B; Rabaeus, M; Salen, P1
Fox, KM; Gandhi, SK; Gold, A; Hsia, J; Jensen, MM; Ohsfeldt, RL; Smolen, LJ1
Genest, J; Glynn, RJ; Kastelein, JJ; Koenig, W; Macfadyen, JG; Nordestgaard, BG; Ridker, PM1
MacDonald, GP2
Addo, J; Cappuccio, FP; Casas, JP; Hingorani, AD; Jeffery, S; Miller, MA; Newcombe, P; Shah, T; Smeeth, L; Strazzullo, P; Tinworth, L; Whittaker, J1
Pietanza, SC; Schena, FP; Vassanelli, C1
Carter, NJ1
Cornuz, J; Marques-Vidal, PM; Nanchen, D; Paccaud, F; Pletcher, MJ; Rodondi, N; Vollenweider, P; Waeber, G1
Eisenberg, T; Wells, MT1
Biron, P; Rose, CP; Vos, E1
Crea, F; Sgueglia, GA1
Breimer, LH; Mikhailidis, DP1
Gallo, P; Rapezzi, C1
Gambetti, S; Romanazzi, S; Urbinati, S1
Perna, GP1
Chu, KM; Han, CL; Li, YH; Lin, GM1
Ara, R; Durrington, PN; Pandor, A; Rafia, R; Rees, A; Reynolds, TM; Stevens, J; Stevenson, M; Ward, SE; Wierzbicki, AS1
Blaha, MJ; Blumenthal, RS; Long, SB; Michos, ED1
Agatston, A; Blaha, MJ; Blankstein, R; Blumenthal, RS; Budoff, MJ; Criqui, MH; Cushman, M; Lakoski, S; Nasir, K; O'Leary, DH; Rivera, JJ; Szklo, M1
Hsia, J; MacFadyen, JG; Monyak, J; Ridker, PM1
Chasman, DI; Glynn, RJ; MacFadyen, JG; Ridker, PM1
Elis, A; Stein, EA; Zhou, R1
Targher, G1
Albert, MA; Ferdinand, KC; Fonseca, FA; Glynn, RJ; Lorenzatti, AJ; MacFadyen, JG; Ridker, PM1
Diamond, GA; Kaul, S; Morrissey, RP1
Day, S1
Breckenridge, A1
Temple, R1
Agatston, A; Blaha, MJ; Blankstein, R; Blumenthal, RS; Budoff, MJ; DeFilippis, AP; Lima, J; Nasir, K; O'Leary, DH; Rivera, JJ1
Allemann, Y; Burow, A; Hess, OM; Klaey, M; Shaw, SG; Wustmann, K1
Cook, NR; Dorresteijn, JA; Paynter, NP; Ridker, PM; Steyerberg, EW; van der Graaf, Y; Visseren, FL; Wassink, AM1
Palomo, L; Sánchez-Robles, G1
Gandhi, SK; Jensen, MM; Ohsfeldt, RL; Olsson, AG; Paulsson, T1
Kataoka, Y; Nicholls, SJ; Uno, K1
Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD1
Serebruany, VL1
Anand, IS1
Kobalava, ZhD; Villeval'de, SV1
Barratt, BJ; Chasman, DI; Chu, AY; Guilianini, F; Nyberg, F; Ridker, PM1
Crook, MA; Jewkes, C; Jones, A; Meek, C; Twomey, PJ; Viljoen, A; Wierzbicki, AS1
Ahn, YK; Baek, SH; Byun, YS; Cho, KI; Choi, DJ; Choi, SW; Choi, YS; Jang, Y; Jeon, DW; Kim, JY; Kim, KS; Kim, YJ; Lee, SH; Min, PK; Rha, SW1
Athyros, VG; Karagiannis, A; Kostapanos, MS; Mikhailidis, DP1
Barratt, BJ; Chasman, DI; Giulianini, F; MacFadyen, J; Nyberg, F; Ridker, PM1
Choudhury, RP; Iacob, AO1
Stein, EA1
Koenig, W; MacFadyen, JG; Ridker, PM; Wolfert, RL1
Agouridis, AP; Challa, A; Elisaf, M; Liberopoulos, EN; Makariou, SE1
Almog, Y; Glynn, RJ; MacFadyen, J; Malhotra, A; Novack, V; Ridker, PM1
Boekholdt, SM; Glynn, RJ; Kastelein, JJ; Mora, S; Nordestgaard, BG; Ridker, PM1
Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB1
Barbosa, SP; Bianco, HT; Fonseca, FA; França, CN; Izar, MC; Kasmas, SH; Mendes, GD; Pinheiro, LF; Povoa, RM1
Musella, F; Paneni, F; Perrone-Filardi, P; Savarese, G; Volpe, M1
Alperin, P; Gandhi, S; Hsia, J; Peskin, B; Schuetz, CA; van Herick, A1
Elis, A; Lishner, M1
Heintjes, EM; Herings, RM; Meerding, WJ; Penning-van Beest, FJ; Plat, AW; Sturkenboom, MC; Webb, K1
Hudzik, B; Polonski, L; Szkodzinski, J1
Colotto, M; Durante, C; Renzi, A1
Gogolashvili, NG1
Ooi, EM; Watts, GF1
Glynn, RJ; Libby, P; MacFadyen, JG; Pradhan, A; Ridker, PM1
Jeong, JW; Kim, NH; Ko, JS; Oh, SK; Rhee, SJ; Shin, SN; Yun, KH1
Alvarez Sanz, C; Barrios, V; Brosa, M; Capel, M; Lobos, JM; Serrano, A1
Drapkina, OM; Korneeva, ON1
Cunha, RV; Domingos, H; Domingos, JA; Paniago, AM; Rodrigues, RL; Souza, AS1
Brito, JP; Montori, VM1
Carney, SL1
Zateĭshchikov, DA1
Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J1
Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; McPeters, G; Pirags, V; Rosen, JB; Triscari, J; Vides, H1
Bernal-Rosales, LP; Cervantes, JL; Gonzalez, JG; Marin, JA; Martinez, G; Ocampo, R; Polanco, A; Rodriguez-Briones, I; Sanchez-Mijangos, H; Talavera, JO1
Korlipara, K1
Owen, OG1
Olsson, A1
Baldasseroni, S; Fabbri, G; Maggioni, AP1
Fox, JC; Schuster, H1
Hirsch, M; Jones, P; O'Donnell, JC1
Ferdinand, KC1
Dunselman, PH; Jukema, JW; Liem, AH; Lok, DJ; van der Sloot, JA; Zwinderman, AH1
Mora, S; Ridker, PM1
Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V1
Berneis, K; Rizzo, M1
Borok, GM; Huse, DM; McDonough, K; Ozminkowski, RJ; Song, X; Williams, SA1
Borok, GM; Huse, DM; Maguire, J; McDonough, K; Ozminkowski, RJ; Song, X; Williams, SA1
De Hert, M; Hanssens, L; Kalnicka, D; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M1
Ballantyne, CM; Duffield, E; Eber, B; Moccetti, T; Sosef, F; Vogt, A; Weiss, R1
Schuster, H1
Stahl, HD1
Bergheanu, SC; Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, A; Van der Bom, JG; Van Tol, A1
Apetrei, E; Barrios, V; Böhm, M; Cleland, JG; Cornel, JH; Dunselman, P; Fonseca, C; Goudev, A; Grande, P; Gullestad, L; Hjalmarson, A; Hradec, J; Jánosi, A; Kamenský, G; Kjekshus, J; Komajda, M; Korewicki, J; Kuusi, T; Mach, F; Mareev, V; McMurray, JJ; Ranjith, N; Schaufelberger, M; van Veldhuisen, DJ; Vanhaecke, J; Waagstein, F; Wedel, H; Wikstrand, J1
Coppey, LJ; Davidson, EP; Kleinschmidt, TL; Lund, DD; Oltman, CL; Yorek, MA1
Lee, YT; Ro, YM; Sim, KH; Sriratanasathavorn, C; Tomlinson, B; Zhu, JR1
Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP1
Orr, JD1
Angermann, CE; Nitschmann, S1
Elisaf, MS; Kostapanos, MS; Milionis, HJ1
Doggrell, SA1
Gandhi, S; Harley, CR; Heien, H; Nelson, SP1
Bruckert, E1
Frishman, WH; Murthy, S; Strom, JA1

Reviews

55 review(s) available for fluorobenzenes and Cardiovascular Diseases

ArticleYear
Pleiotropic antioxidant potential of rosuvastatin in preventing cardiovascular disorders.
    European journal of pharmacology, 2013, Jul-05, Volume: 711, Issue:1-3

    Topics: Animals; Antioxidants; Cardiovascular Diseases; Fluorobenzenes; Humans; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2013
An update on the benefits and risks of rosuvastatin therapy.
    Postgraduate medicine, 2014, Volume: 126, Issue:2

    Topics: Atherosclerosis; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2014
Lipid-lowering efficacy of rosuvastatin.
    The Cochrane database of systematic reviews, 2014, Nov-21, Issue:11

    Topics: Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Triglycerides

2014
[Lipid lowering by rosuvastatin: how do statins differ?].
    Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:5

    Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Survival Rate

2015
[Choosing wisely when prescribing statins].
    Nederlands tijdschrift voor geneeskunde, 2015, Volume: 159

    Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Quality of Health Care; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2015
[Efficacy and Safety of Rosuvastatin in Patients of Different Risk Groups of Developing Cardiovascular Diseases].
    Kardiologiia, 2015, Volume: 55, Issue:2

    Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Morbidity; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Russia; Secondary Prevention; Sulfonamides; Treatment Outcome

2015
Rosuvastatin Treatment for Preventing Contrast-Induced Acute Kidney Injury After Cardiac Catheterization: A Meta-Analysis of Randomized Controlled Trials.
    Medicine, 2015, Volume: 94, Issue:30

    Topics: Acute Kidney Injury; Cardiac Catheterization; Cardiovascular Diseases; Contrast Media; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2015
[Cardiology 2008].
    Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:25-26

    Topics: Anticholesteremic Agents; Antihypertensive Agents; Aortic Valve Stenosis; Cardiac Catheterization; Cardiovascular Diseases; Drug Therapy, Combination; Electrocardiography; Fluorobenzenes; Heart Failure; Heart Valve Prosthesis Implantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2008
Clinical efficacy and safety of statins in managing cardiovascular risk.
    Vascular health and risk management, 2008, Volume: 4, Issue:2

    Topics: Atherosclerosis; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Muscular Diseases; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2008
Rosuvastatin and progression of atherosclerosis.
    Expert review of cardiovascular therapy, 2008, Volume: 6, Issue:7

    Topics: Atherosclerosis; Cardiovascular Diseases; Carotid Arteries; Coronary Vessels; Disease Progression; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2008
Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?
    International journal of clinical practice, 2009, Volume: 63, Issue:3

    Topics: Aged; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
Lipid lowering for primary prevention.
    Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670

    Topics: Aged; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Meta-Analysis as Topic; Primary Prevention; Proportional Hazards Models; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Treatment Outcome

2009
Efficacy and safety of rosuvastatin in the management of dyslipidemia.
    Vascular health and risk management, 2009, Volume: 5, Issue:1

    Topics: Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Treatment Outcome

2009
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Advances in therapy, 2009, Volume: 26, Issue:5

    Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Evidence-Based Medicine; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Kidney Failure, Chronic; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:4

    Topics: Angina, Unstable; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fluorobenzenes; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome

2009
The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
    Postgraduate medicine, 2009, Volume: 121, Issue:3

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Gravity Sensing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
Moving toward new statin guidelines in a post-JUPITER world: principles to consider.
    Current atherosclerosis reports, 2009, Volume: 11, Issue:4

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Practice Guidelines as Topic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2009
[The JUPITER trial: a new approach in primary prevention].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2009, Volume: 37 Suppl 4

    Topics: C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2009
The JUPITER trial: How will it change clinical practice?
    Reviews in cardiovascular medicine, 2009,Spring, Volume: 10, Issue:2

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multicenter Studies as Topic; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.
    Current vascular pharmacology, 2009, Volume: 7, Issue:3

    Topics: Cardiovascular Diseases; Drug Administration Schedule; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Randomized Controlled Trials as Topic; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides

2009
Rediscovering bile acid sequestrants.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:12

    Topics: Allylamine; Anticholesteremic Agents; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fluorobenzenes; Humans; Hypoglycemic Agents; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2009
[From lipid target values to the JUPITER study. Significance of achieving lipid levels specified by the guidelines and deficiencies in practice].
    Orvosi hetilap, 2009, Nov-01, Volume: 150, Issue:44

    Topics: Aged; Atherosclerosis; Attitude of Health Personnel; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Prescriptions; Family Practice; Female; Fluorobenzenes; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Expectancy; Lipids; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2009
Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA.
    Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:11

    Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Primary Prevention; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2009
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.
    Vascular health and risk management, 2009, Volume: 5

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Evidence-Based Medicine; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
[The role of statins in the treatment of heart failure].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2009, Volume: 37, Issue:7

    Topics: Cardiovascular Diseases; Coronary Disease; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2009
Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
    The American journal of cardiology, 2010, Jan-01, Volume: 105, Issue:1

    Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2010
Cardiovascular risk in uremic patients: darkness after AURORA.
    Renal failure, 2010, Volume: 32, Issue:2

    Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipids; Patient Dropouts; Patient Selection; Pyrimidines; Randomized Controlled Trials as Topic; Renal Dialysis; Research Design; Risk; Rosuvastatin Calcium; Sulfonamides; Uremia

2010
Should we measure C-reactive protein on earth or just on JUPITER?
    Clinical cardiology, 2010, Volume: 33, Issue:4

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2010
Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.
    Archives of internal medicine, 2010, Jun-28, Volume: 170, Issue:12

    Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; Fluorobenzenes; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2010
Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction.
    Circulation. Cardiovascular genetics, 2010, Volume: 3, Issue:5

    Topics: C-Reactive Protein; Cardiovascular Diseases; Ethnicity; Europe; Fluorobenzenes; Genetics, Population; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Polymorphism, Single Nucleotide; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; United States

2010
Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010, Volume: 10, Issue:6

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2010
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
    Drug design, development and therapy, 2010, Dec-09, Volume: 4

    Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2010
Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly.
    Clinical interventions in aging, 2011, Volume: 6

    Topics: Aged; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides

2011
Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
    Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:11

    Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2011
[Statins in primary prophylaxis of cardiovascular diseases].
    Terapevticheskii arkhiv, 2011, Volume: 83, Issue:9

    Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Primary Prevention; Pyrimidines; Risk; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2011
Targeting HDL-cholesterol to reduce residual cardiovascular risk.
    Current opinion in lipidology, 2012, Volume: 23, Issue:2

    Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2012
Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis.
    International journal of cardiology, 2013, Sep-10, Volume: 167, Issue:6

    Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2013
Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2012, Volume: 22, Issue:9

    Topics: Adolescent; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Databases, Factual; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult

2012
Non-every day statin administration--a literature review.
    European journal of internal medicine, 2012, Volume: 23, Issue:5

    Topics: Atorvastatin; Cardiovascular Diseases; Drug Administration Schedule; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2012
[Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine].
    Kardiologiia, 2012, Volume: 52, Issue:7

    Topics: Atorvastatin; Biological Availability; Cardiovascular Diseases; Dose-Response Relationship, Drug; Evidence-Based Medicine; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Therapeutic Equivalency

2012
[How to prolong life of patients at high cardiovascular risk. Features of rosuvastatin].
    Kardiologiia, 2012, Volume: 52, Issue:8

    Topics: Cardiovascular Diseases; Fluorobenzenes; Global Health; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Survival Rate

2012
[Features of the use of rosuvastatin in clinical practice].
    Kardiologiia, 2012, Volume: 52, Issue:11

    Topics: Biological Availability; Cardiovascular Diseases; Comorbidity; Fluorobenzenes; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Metabolic Clearance Rate; Pharmacogenetics; Pharmacovigilance; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tissue Distribution; Treatment Outcome

2012
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
    Circulation, 2003, Nov-11, Volume: 108, Issue:19

    Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2003
Statins: how far have we come? A review of rosuvastatin.
    International journal of clinical practice. Supplement, 2003, Issue:137

    Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2003
[Ongoing trials and future prospects].
    Italian heart journal : official journal of the Italian Federation of Cardiology, 2003, Volume: 4 Suppl 7

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Fluorobenzenes; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2003
Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:11

    Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Interactions; Drug Labeling; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Product Surveillance, Postmarketing; Pyrimidines; Randomized Controlled Trials as Topic; Rhabdomyolysis; Risk Assessment; Rosuvastatin Calcium; Sulfonamides

2005
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    The American journal of cardiology, 2006, Jan-16, Volume: 97, Issue:2A

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2006
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:2 Pt 1

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors

2006
The clinical relevance of low-density-lipoproteins size modulation by statins.
    Cardiovascular drugs and therapy, 2006, Volume: 20, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Particle Size; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2006
The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk.
    Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:2

    Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation Mediators; Male; Maximum Tolerated Dose; Program Evaluation; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides

2007
Statins in the spectrum of neurologic disease.
    Current atherosclerosis reports, 2008, Volume: 10, Issue:1

    Topics: Alzheimer Disease; Animals; Atherosclerosis; Cardiovascular Diseases; Diabetic Neuropathies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Multiple Sclerosis; Nervous System Diseases; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Pyrimidines; Reactive Oxygen Species; Rosuvastatin Calcium; Stroke; Sulfonamides

2008
An overview of the extra-lipid effects of rosuvastatin.
    Journal of cardiovascular pharmacology and therapeutics, 2008, Volume: 13, Issue:3

    Topics: Animals; Cardiotonic Agents; Cardiovascular Diseases; Central Nervous System; Fibrinolytic Agents; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Nervous System; Peripheral Nervous System; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2008
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
    Reviews on recent clinical trials, 2006, Volume: 1, Issue:2

    Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2006
New advances in lipid-modifying therapies for reducing cardiovascular risk.
    Cardiology, 2002, Volume: 97, Issue:2

    Topics: Acetamides; Acetates; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Sulfonic Acids

2002
Ultra-short-acting beta-adrenergic blockers.
    The Medical clinics of North America, 1988, Volume: 72, Issue:2

    Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Fluorobenzenes; Humans; Hypotension; Propanolamines

1988

Trials

50 trial(s) available for fluorobenzenes and Cardiovascular Diseases

ArticleYear
Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.
    Stroke, 2022, Volume: 53, Issue:10

    Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Disease Progression; Fluorobenzenes; Humans; Lipids; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2022
Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
    European journal of clinical investigation, 2013, Volume: 43, Issue:7

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoproteins B; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Pilot Projects; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors

2013
Achieving recommended low density lipoprotein cholesterol goals and the factors associated with target achievement of hypercholesterolemia patients with rosuvastatin in primary care.
    Current medical research and opinion, 2013, Volume: 29, Issue:7

    Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Pyrimidines; Republic of Korea; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Smoking; Sulfonamides; Surveys and Questionnaires

2013
Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
    American heart journal, 2013, Volume: 165, Issue:6

    Topics: Alleles; Cardiovascular Diseases; DNA; Double-Blind Method; Fluorobenzenes; Follow-Up Studies; Gene Frequency; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Organic Anion Transporters; Polymorphism, Genetic; Primary Prevention; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2013
The impact of variability in ultrasound settings on the measured echolucency of the carotid intima-media.
    Journal of hypertension, 2013, Volume: 31, Issue:9

    Topics: Adult; Calibration; Cardiovascular Diseases; Carotid Arteries; Carotid Intima-Media Thickness; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Pyrimidines; Reproducibility of Results; Risk Factors; Rosuvastatin Calcium; Software; Sulfonamides; Time Factors

2013
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Clinical therapeutics, 2013, Volume: 35, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Young Adult

2013
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.
    Circulation, 2013, Sep-10, Volume: 128, Issue:11

    Topics: Aged; Angina, Unstable; Apolipoprotein A-I; Asymptomatic Diseases; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Endpoint Determination; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Nuclear Magnetic Resonance, Biomolecular; Particle Size; Proportional Hazards Models; Pyrimidines; Risk; Rosuvastatin Calcium; Single-Blind Method; Stroke; Sulfonamides; Triglycerides

2013
Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial.
    Journal of atherosclerosis and thrombosis, 2014, Volume: 21, Issue:2

    Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prognosis; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine

2014
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
    Circulation, 2014, Feb-11, Volume: 129, Issue:6

    Topics: Aged; Black People; Cardiovascular Diseases; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lipoprotein(a); Male; Middle Aged; Placebos; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; White People

2014
Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy.
    The Journal of infectious diseases, 2014, Apr-15, Volume: 209, Issue:8

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Anti-Retroviral Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrimidines; Regression Analysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Vasculitis

2014
Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.
    Scandinavian journal of clinical and laboratory investigation, 2014, Volume: 74, Issue:4

    Topics: Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Male; Middle Aged; Pyrimidines; Pyrroles; Quinolines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2014
Can intensive lipid-lowering therapy improve the carotid intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease?: The JART and JART extension subanalysis.
    Journal of atherosclerosis and thrombosis, 2014, Volume: 21, Issue:7

    Topics: Aged; Cardiovascular Diseases; Carotid Intima-Media Thickness; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Middle Aged; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2014
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies
    Clinical cardiology, 2014, Volume: 37, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2014
Rosuvastatin may reduce the incidence of cardiovascular events in patients with acute coronary syndromes receiving percutaneous coronary intervention by suppressing miR-155/SHIP-1 signaling pathway.
    Cardiovascular therapeutics, 2014, Volume: 32, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Cytokines; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inositol Polyphosphate 5-Phosphatases; Male; MicroRNAs; Middle Aged; Percutaneous Coronary Intervention; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoric Monoester Hydrolases; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; T-Lymphocytes, Regulatory

2014
Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults.
    AIDS (London, England), 2015, Jan-14, Volume: 29, Issue:2

    Topics: Absorptiometry, Photon; Adult; Biomarkers; Body Composition; Bone Density; Cardiovascular Diseases; Female; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Osteoporosis; Pyrimidines; Receptors, Tumor Necrosis Factor, Type I; Regression Analysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2015
Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial.
    AIDS (London, England), 2015, Jan-28, Volume: 29, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Anticholesteremic Agents; Cardiovascular Diseases; Enzyme-Linked Immunosorbent Assay; Female; Fluorobenzenes; HIV Infections; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Placebos; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2015
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
    The New England journal of medicine, 2008, Nov-20, Volume: 359, Issue:21

    Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Proportional Hazards Models; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides

2008
Is hsCRP Back on Board? Implications from the JUPITER Trial.
    Clinical chemistry, 2009, Volume: 55, Issue:2

    Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Predictive Value of Tests; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2009
Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study.
    Clinical chemistry, 2009, Volume: 55, Issue:2

    Topics: Aged; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Data Interpretation, Statistical; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Regression Analysis; Rosuvastatin Calcium; Sulfonamides

2009
[JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
    Revue medicale de Liege, 2008, Volume: 63, Issue:12

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States

2008
Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) st
    Journal of the American College of Cardiology, 2009, Mar-17, Volume: 53, Issue:11

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Nutrition Surveys; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; United States

2009
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670

    Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Disease-Free Survival; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sensitivity and Specificity; Statistics, Nonparametric; Sulfonamides; Treatment Outcome

2009
A randomized trial of rosuvastatin in the prevention of venous thromboembolism.
    The New England journal of medicine, 2009, Apr-30, Volume: 360, Issue:18

    Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Pulmonary Embolism; Pyrimidines; Risk; Rosuvastatin Calcium; Sulfonamides; Venous Thromboembolism; Venous Thrombosis

2009
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrimidines; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides; Treatment Failure

2009
Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study.
    Vascular health and risk management, 2008, Volume: 4, Issue:6

    Topics: Aged; Cardiovascular Diseases; Estonia; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome

2008
Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Future cardiology, 2009, Volume: 5, Issue:3

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Confidence Intervals; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Risk; Risk Assessment; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Venous Thromboembolism

2009
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
    Annals of internal medicine, 2010, Apr-20, Volume: 152, Issue:8

    Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2010
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    International journal of clinical practice, 2010, Volume: 64, Issue:8

    Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome

2010
Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvas
    Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:5

    Topics: Aged; C-Reactive Protein; Canada; Cardiovascular Diseases; Cholesterol, LDL; Evidence-Based Medicine; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Risk; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2010
Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastati
    Journal of the American College of Cardiology, 2011, Apr-19, Volume: 57, Issue:16

    Topics: Aged; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2011
Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
    American heart journal, 2011, Volume: 162, Issue:1

    Topics: Aged; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Ethnicity; Female; Fluorobenzenes; Follow-Up Studies; Global Health; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Prevalence; Primary Prevention; Pyrimidines; Racial Groups; Rosuvastatin Calcium; Sulfonamides; Survival Rate; Treatment Outcome

2011
Additive effect of homocysteine- and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular disease.
    Cardiovascular therapeutics, 2012, Volume: 30, Issue:5

    Topics: Aged; Anticholesteremic Agents; Brachial Artery; Cardiovascular Diseases; Double-Blind Method; Endothelium; Endpoint Determination; Female; Fluorobenzenes; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Patient Compliance; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vasodilation; Vitamin B Complex; Vitamins

2012
Estimating treatment effects for individual patients based on the results of randomised clinical trials.
    BMJ (Clinical research ed.), 2011, Oct-03, Volume: 343

    Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Data Interpretation, Statistical; Female; Fluorobenzenes; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Biological; Models, Statistical; Patient Selection; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2011
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2011
Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.
    Circulation. Cardiovascular genetics, 2012, Feb-01, Volume: 5, Issue:1

    Topics: Apolipoproteins E; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Genome-Wide Association Study; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pyrimidines; Receptors, Lysophosphatidic Acid; Rosuvastatin Calcium; Sulfonamides

2012
Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia.
    Atherosclerosis, 2012, Volume: 221, Issue:1

    Topics: Aged; Asian People; Biomarkers; Blood Glucose; Blood Urea Nitrogen; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Creatinine; Drug Combinations; Enzymes; Female; Fenofibrate; Fluorobenzenes; Hemoglobins; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Liver; Male; Middle Aged; Muscle, Skeletal; Patient Selection; Pyrimidines; Republic of Korea; Rhabdomyolysis; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome

2012
Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
    Circulation. Cardiovascular genetics, 2012, Apr-01, Volume: 5, Issue:2

    Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Genome-Wide Association Study; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2012
Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
    Journal of cardiovascular pharmacology and therapeutics, 2012, Volume: 17, Issue:4

    Topics: 25-Hydroxyvitamin D 2; Adult; Aged; Calcifediol; Cardiovascular Diseases; Combined Modality Therapy; Dietary Supplements; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2012
The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2012, Apr-17, Volume: 184, Issue:7

    Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Pneumonia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2012
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.
    Lancet (London, England), 2012, Aug-11, Volume: 380, Issue:9841

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States; Venous Thromboembolism

2012
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:6

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2013
A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
    Diabetes & vascular disease research, 2013, Volume: 10, Issue:3

    Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Combinations; Drug Monitoring; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides

2013
A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients.
    Current medical research and opinion, 2013, Volume: 29, Issue:4

    Topics: Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metabolic Syndrome; Mexico; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides

2013
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.
    Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:5

    Topics: Cardiovascular Diseases; Data Collection; Double-Blind Method; Fluorobenzenes; Humans; Lipoproteins, LDL; Meta-Analysis as Topic; Pyrimidines; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2004
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2005, Volume: 12, Issue:1

    Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2005
LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Current medical research and opinion, 2005, Volume: 21, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2005
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
    The American journal of cardiology, 2007, Mar-01, Volume: 99, Issue:5

    Topics: Aged; Azetidines; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2007
Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
    Current medical research and opinion, 2007, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Aryldialkylphosphatase; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Dose-Response Relationship, Drug; Double-Blind Method; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2007
Rosuvastatin in older patients with systolic heart failure.
    The New England journal of medicine, 2007, Nov-29, Volume: 357, Issue:22

    Topics: Aged; Cardiovascular Diseases; Female; Fluorobenzenes; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Proportional Hazards Models; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides; Systole; Treatment Outcome

2007
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).
    Current medical research and opinion, 2007, Volume: 23, Issue:12

    Topics: Anticholesteremic Agents; Asia; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2007

Other Studies

141 other study(ies) available for fluorobenzenes and Cardiovascular Diseases

ArticleYear
Factors associated with statin selection among privately insured commercial and Medicare patients.
    Current medical research and opinion, 2013, Volume: 29, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult

2013
Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study.
    European heart journal, 2013, Volume: 34, Issue:18

    Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; England; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Patient Selection; Prospective Studies; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides

2013
The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITER.
    European heart journal, 2013, Volume: 34, Issue:18

    Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2013
Statins work around the world.
    Current medical research and opinion, 2013, Volume: 29, Issue:7

    Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2013
Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
    European journal of preventive cardiology, 2013, Volume: 20, Issue:6

    Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Databases, Factual; Dose-Response Relationship, Drug; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Odds Ratio; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome

2013
Risk of incident diabetes among patients treated with statins: population based study.
    BMJ (Clinical research ed.), 2013, May-23, Volume: 346

    Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2013
Prevalence and types of persistent dyslipidemia in patients treated with statins.
    Croatian medical journal, 2013, Volume: 54, Issue:4

    Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Croatia; Cross-Sectional Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prevalence; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides

2013
Will statins be an effective anti-inflammatory intervention for prevention of cardiovascular disease in patients with HIV?
    The Journal of infectious diseases, 2014, Apr-15, Volume: 209, Issue:8

    Topics: Anti-Retroviral Agents; Cardiovascular Diseases; Female; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vasculitis

2014
Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.
    Clinical therapeutics, 2014, Jan-01, Volume: 36, Issue:1

    Topics: Aged; Atorvastatin; Cardiovascular Diseases; Computer Simulation; Drug Substitution; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Middle Aged; Models, Biological; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2014
Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects.
    European heart journal, 2014, Volume: 35, Issue:13

    Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Numbers Needed To Treat; Precision Medicine; Professional Practice; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides

2014
Lipoprotein(a): there's life in the old dog yet.
    Circulation, 2014, Feb-11, Volume: 129, Issue:6

    Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2014
Longitudinal association between body mass index and health-related quality of life.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Aged; Body Mass Index; Cardiovascular Diseases; Cross-Sectional Studies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Obesity; Pyrimidines; Quality of Life; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2014
LDL-C levels in US patients at high cardiovascular risk receiving rosuvastatin monotherapy.
    Clinical therapeutics, 2014, Volume: 36, Issue:5

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; International Classification of Diseases; Male; Middle Aged; Pyrimidines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States

2014
Letter by Giral et al regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastati
    Circulation, 2014, Oct-21, Volume: 130, Issue:17

    Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Pyrimidines; Sulfonamides

2014
Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"
    Circulation, 2014, Oct-21, Volume: 130, Issue:17

    Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Pyrimidines; Sulfonamides

2014
Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
    Arquivos brasileiros de cardiologia, 2015, Volume: 104, Issue:1

    Topics: Aged; Aged, 80 and over; Atorvastatin; Brazil; Cardiovascular Diseases; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Economic; National Health Programs; Primary Prevention; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides

2015
The effect of infrequent low-dose rosuvastatin on the lipid profile.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2014
Rosuvastatin reduced major cardiovascular events in patients at intermediate cardiovascular risk.
    Annals of internal medicine, 2016, 07-19, Volume: 165, Issue:2

    Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2016
Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients.
    Journal of thrombosis and thrombolysis, 2009, Volume: 28, Issue:2

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Ticlopidine

2009
I am 72, had a heart attack 16 years ago, and had angioplasty at Cleveland Clinic. My LDL was over 100 and HDL was in the low 30s. I take rosuvastatin and now my LDL is below 70, but my HDL has been driven down also, to 22. I am unable to raise HDL ind
    Heart advisor, 2008, Volume: 11, Issue:5

    Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2008
Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia.
    Journal of lipid research, 2009, Volume: 50, Issue:1

    Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Dextrans; Endothelium; Fluorobenzenes; Glycocalyx; Heterozygote; Humans; Hypercholesterolemia; Male; Middle Aged; Permeability; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2009
Expanding the orbit of primary prevention--moving beyond JUPITER.
    The New England journal of medicine, 2008, Nov-20, Volume: 359, Issue:21

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2008
Cardiovascular health. Statin therapy reduces disease in healthy volunteers--but how, exactly?
    Science (New York, N.Y.), 2008, Nov-14, Volume: 322, Issue:5904

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2008
Studies examine inflammatory biomarker in prevention and prediction of heart disease.
    JAMA, 2009, Jan-07, Volume: 301, Issue:1

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides

2009
[Sequelae of the JUPITER study. What is changing in primary prevention? (interview by Dr. med. Dirk Einecke)].
    MMW Fortschritte der Medizin, 2008, Dec-04, Volume: 150, Issue:49-50

    Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Multicenter Studies as Topic; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2008
[Statin cuts cardiovascular risk in half].
    MMW Fortschritte der Medizin, 2008, Dec-04, Volume: 150, Issue:49-50

    Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Survival Rate

2008
Concern still warranted: medication burden and persistence with lipid-lowering drugs.
    The American journal of managed care, 2009, Volume: 15, Issue:1

    Topics: C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2009
[Comment from the lipidologic viewpoint].
    Praxis, 2009, Feb-04, Volume: 98, Issue:3

    Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Data Interpretation, Statistical; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primary Prevention; Prospective Studies; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors

2009
[Comment from the cardiologic viewpoint].
    Praxis, 2009, Feb-04, Volume: 98, Issue:3

    Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2009
[Comment from the family practice viewpoint].
    Praxis, 2009, Feb-04, Volume: 98, Issue:3

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Family Practice; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2009
Jupiter to Earth: CRP promotes atherothrombosis.
    Metabolic syndrome and related disorders, 2009, Volume: 7, Issue:1

    Topics: Aged; Animals; Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Middle Aged; Multicenter Studies as Topic; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
JUPITER strikes earth.
    Nature clinical practice. Cardiovascular medicine, 2009, Volume: 6, Issue:3

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
The Jupiter trial: key findings, controversies, and implications.
    Current cardiology reports, 2009, Volume: 11, Issue:2

    Topics: Aged; C-Reactive Protein; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Decision Making; Evidence-Based Medicine; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2009
Study stirs debate about statin use in those without high cholesterol.
    Mayo Clinic women's healthsource, 2009, Volume: 13, Issue:4

    Topics: Aged; Cardiovascular Diseases; Cholesterol; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; United States

2009
JUPITER clinical directions--polling results.
    The New England journal of medicine, 2009, Mar-05, Volume: 360, Issue:10

    Topics: Adult; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Laboratory Techniques; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Screening; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2009
Rosuvastatin in patients with elevated C-reactive protein.
    The New England journal of medicine, 2009, Mar-05, Volume: 360, Issue:10

    Topics: Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fluorobenzenes; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Smoking; Sulfonamides

2009
Rosuvastatin in patients with elevated C-reactive protein.
    The New England journal of medicine, 2009, Mar-05, Volume: 360, Issue:10

    Topics: Asian People; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2009
Rosuvastatin in patients with elevated C-reactive protein.
    The New England journal of medicine, 2009, Mar-05, Volume: 360, Issue:10

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multivariate Analysis; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Survival Analysis

2009
Rosuvastatin in patients with elevated C-reactive protein.
    The New England journal of medicine, 2009, Mar-05, Volume: 360, Issue:10

    Topics: Cardiovascular Diseases; Diabetes Mellitus; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrimidines; Risk; Rosuvastatin Calcium; Sulfonamides

2009
Rosuvastatin in patients with elevated C-reactive protein.
    The New England journal of medicine, 2009, Mar-05, Volume: 360, Issue:10

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2009
Rosuvastatin in patients with elevated C-reactive protein.
    The New England journal of medicine, 2009, Mar-05, Volume: 360, Issue:10

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cause of Death; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Pyrimidines; Risk; Rosuvastatin Calcium; Sulfonamides

2009
Rosuvastatin in patients with elevated C-reactive protein.
    The New England journal of medicine, 2009, Mar-05, Volume: 360, Issue:10

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Data Interpretation, Statistical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Risk; Rosuvastatin Calcium; Sulfonamides

2009
Rosuvastatin in patients with elevated C-reactive protein.
    The New England journal of medicine, 2009, Mar-05, Volume: 360, Issue:10

    Topics: Bias; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Data Interpretation, Statistical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Research Design; Risk; Rosuvastatin Calcium; Sulfonamides

2009
[JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
    Nederlands tijdschrift voor geneeskunde, 2009, Feb-07, Volume: 153, Issue:6

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cost-Benefit Analysis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States

2009
[JUPITER study (2). For now no reason to give statins to more people].
    Nederlands tijdschrift voor geneeskunde, 2009, Feb-07, Volume: 153, Issue:6

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Practice Guidelines as Topic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States

2009
[Less vascular risk with rosuvastatin in elevated CRP].
    Nederlands tijdschrift voor geneeskunde, 2009, Feb-07, Volume: 153, Issue:6

    Topics: C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
Is diabetes the cost to pay for a greater cardiovascular prevention?
    International journal of cardiology, 2010, Oct-08, Volume: 144, Issue:2

    Topics: Cardiovascular Diseases; Diabetes Mellitus; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2010
Bringing JUPITER down to earth.
    Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Global Health; Health Services Needs and Demand; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Primary Prevention; Prospective Studies; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides

2009
Sunset for statins after AURORA?
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides; Treatment Failure

2009
The editor's roundtable: the JUPITER trial--initial results and clinical implications.
    The American journal of cardiology, 2009, May-15, Volume: 103, Issue:10

    Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Multicenter Studies as Topic; Patient Selection; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
[JUPITER study, more reason to give statins as preventive measure - commentary].
    Kardiologia polska, 2009, Volume: 67, Issue:3

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Comorbidity; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Treatment Outcome

2009
[The JUPITER study].
    Giornale italiano di cardiologia (2006), 2009, Volume: 10, Issue:5

    Topics: C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2009
The Jupiter trial--new territory for statins?
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:7

    Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2009
Rosuvastatin in patients undergoing hemodialysis.
    The New England journal of medicine, 2009, Jul-02, Volume: 361, Issue:1

    Topics: Cardiovascular Diseases; Confounding Factors, Epidemiologic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperphosphatemia; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Phosphorus; Pyrimidines; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides

2009
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Screening; Patient Selection; Pyrimidines; Research Design; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Causality; Cholesterol, LDL; Confounding Factors, Epidemiologic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Polymorphism, Genetic; Pyrimidines; Research Design; Rosuvastatin Calcium; Sulfonamides

2009
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrimidines; Research Design; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrimidines; Research Design; Rosuvastatin Calcium; Sulfonamides

2009
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Research Design; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Research Design; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Research Design; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
Rosuvastatin in patients undergoing hemodialysis.
    The New England journal of medicine, 2009, Jul-02, Volume: 361, Issue:1

    Topics: Cardiovascular Diseases; Diabetes Complications; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2009
Rosuvastatin in patients undergoing hemodialysis.
    The New England journal of medicine, 2009, Jul-02, Volume: 361, Issue:1

    Topics: Age Factors; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
Most would fail to benefit from JUPITER Intervention.
    Journal of the American College of Cardiology, 2009, Aug-18, Volume: 54, Issue:8

    Topics: Adult; Aged; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Primary Prevention; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Statistics as Topic; Sulfonamides; Survival Analysis; United States

2009
Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study.
    Current medical research and opinion, 2009, Volume: 25, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cohort Studies; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Male; Middle Aged; Netherlands; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Time Factors; Young Adult

2009
Rosuvastatin for cardiovascular prevention: too many uncertainties.
    Prescrire international, 2009, Volume: 18, Issue:102

    Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; Uncertainty

2009
Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:9

    Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Stroke; Sulfonamides

2009
Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice.
    Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Primary Prevention; Propensity Score; Pyrimidines; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Treatment Outcome

2009
Another look at the results of the JUPITER trial.
    The American journal of cardiology, 2009, Dec-01, Volume: 104, Issue:11

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus; Female; Fluorobenzenes; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
Clinical trial update II: Jupiter trial, rosuvastatin has greater efficacy in elderly populations.
    European heart journal, 2009, Volume: 30, Issue:23

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2009
The JUPITER trial: results, controversies, and implications for prevention.
    Circulation. Cardiovascular quality and outcomes, 2009, Volume: 2, Issue:3

    Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
Public health. U.S. panel favors wider use of preventive drug treatment.
    Science (New York, N.Y.), 2010, Jan-08, Volume: 327, Issue:5962

    Topics: Advisory Committees; C-Reactive Protein; Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; United States; United States Food and Drug Administration

2010
Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice?
    PLoS medicine, 2010, Feb-02, Volume: 7, Issue:2

    Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Evidence-Based Medicine; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Predictive Value of Tests; Pyrimidines; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Unnecessary Procedures

2010
The numbers are in: statins for the primary prevention of cardiovascular disease in women.
    Circulation, 2010, Mar-09, Volume: 121, Issue:9

    Topics: Adult; Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Early Termination of Clinical Trials; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sex Factors; Sulfonamides; Treatment Outcome

2010
Is Jupiter also a god of primary prevention?
    Texas Heart Institute journal, 2010, Volume: 37, Issue:1

    Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome

2010
FDA approves a statin therapy for some: certain, asymptomatic individuals targeted.
    JAMA, 2010, Apr-07, Volume: 303, Issue:13

    Topics: Aged; Cardiovascular Diseases; Drug Approval; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; United States; United States Food and Drug Administration

2010
Summaries for patients. Rosuvastatin to prevent heart problems and stroke in persons 70 years or older.
    Annals of internal medicine, 2010, Apr-20, Volume: 152, Issue:8

    Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2010
Statins for primary prevention in older adults: who is high risk, who is old, and what denotes primary prevention?
    Annals of internal medicine, 2010, Apr-20, Volume: 152, Issue:8

    Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2010
JUPITER, rosuvastatin, and the European Medicines Agency.
    Lancet (London, England), 2010, Jun-12, Volume: 375, Issue:9731

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Drug Approval; European Union; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2010
New analysis supports expanded use of statins in women.
    Harvard women's health watch, 2010, Volume: 17, Issue:8

    Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver; Middle Aged; Muscular Diseases; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; United States; Women's Health

2010
Rosuvastatin and vitamin D: might there be hypovitaminosis D on JUPITER?
    International journal of cardiology, 2010, Dec-03, Volume: 145, Issue:3

    Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Vitamin D; Vitamin D Deficiency

2010
Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial.
    Journal of medical economics, 2010, Volume: 13, Issue:3

    Topics: Aged; Cardiovascular Diseases; Computer Simulation; Cost-Benefit Analysis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Monte Carlo Method; Pyrimidines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Survival Analysis; United States

2010
Was the FDA misled by JUPITER?
    The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:8

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Approval; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; United States; United States Food and Drug Administration

2010
Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein.
    The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:8

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cost-Benefit Analysis; Diagnosis-Related Groups; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Markov Chains; Models, Statistical; Primary Prevention; Pyrimidines; Quality-Adjusted Life Years; Risk Assessment; Rosuvastatin Calcium; South Dakota; Sulfonamides; United States; United States Food and Drug Administration

2010
[The AURORA study].
    Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:6

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Placebos; Prospective Studies; Pyrimidines; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors

2010
The JUPITER Trial: responding to the critics.
    The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9

    Topics: Bayes Theorem; C-Reactive Protein; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2010
Public health impact of statin prescribing strategies based on JUPITER.
    Preventive medicine, 2011, Volume: 52, Issue:2

    Topics: Adult; Aged; Cardiovascular Diseases; Cross-Sectional Studies; Drug Utilization; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Public Health; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Survival Analysis; Switzerland; Treatment Outcome

2011
Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention:
    Circulation, 2010, Dec-07, Volume: 122, Issue:23

    Topics: C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2010
Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Interve
    Circulation, 2010, Dec-07, Volume: 122, Issue:23

    Topics: C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2010
The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?
    Journal of cardiovascular medicine (Hagerstown, Md.), 2011, Volume: 12, Issue:1

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Disease-Free Survival; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2011
Trials by independent expert bodies.
    Archives of internal medicine, 2010, Dec-13, Volume: 170, Issue:22

    Topics: Cardiovascular Diseases; Drug Approval; Expert Testimony; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2010
[The JUPITER study: background and research hypotheses].
    Giornale italiano di cardiologia (2006), 2009, Volume: 10, Issue:11-12 Supp

    Topics: Biomedical Research; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2009
[The JUPITER study: critical review of final results].
    Giornale italiano di cardiologia (2006), 2009, Volume: 10, Issue:11-12 Supp

    Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2009
[JUPITER, what now?].
    Giornale italiano di cardiologia (2006), 2009, Volume: 10, Issue:11-12 Supp

    Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2009
What else does the JUPITER trial add regarding C-reactive protein and cardiovascular disease?
    International journal of cardiology, 2011, Jun-16, Volume: 149, Issue:3

    Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2011
Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
    European journal of preventive cardiology, 2012, Volume: 19, Issue:3

    Topics: Atorvastatin; Bayes Theorem; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Costs; Drug Prescriptions; Drugs, Generic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Markov Chains; Medication Adherence; Models, Economic; Pyrimidines; Pyrroles; Quality Indicators, Health Care; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome

2012
Association between obesity, high-sensitivity C-reactive protein ≥2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis.
    Arteriosclerosis, thrombosis, and vascular biology, 2011, Volume: 31, Issue:6

    Topics: Adult; Aged; Atherosclerosis; Body Mass Index; C-Reactive Protein; Calcium; Cardiovascular Diseases; Carotid Arteries; Clinical Trials as Topic; Cross-Sectional Studies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Obesity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tunica Intima; Tunica Media; Waist Circumference

2011
Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
    Circulation. Cardiovascular genetics, 2011, Volume: 4, Issue:3

    Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Middle Aged; Placebos; Polymorphism, Genetic; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2011
Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
    The American journal of cardiology, 2011, Jul-15, Volume: 108, Issue:2

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Child; Child, Preschool; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Myocardial Revascularization; Niacin; Ohio; Pyrimidines; Registries; Rosuvastatin Calcium; Sulfonamides; Vitamin B Complex; Young Adult

2011
High-sensitivity C-reactive protein, obesity, and subclinical atherosclerosis: implications of JUPITER from the MESA study.
    Arteriosclerosis, thrombosis, and vascular biology, 2011, Volume: 31, Issue:6

    Topics: Aged; Aged, 80 and over; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Obesity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2011
Rosuvastatin and primary cardiovascular prevention. Continue to use pravastatin or simvastatin.
    Prescrire international, 2011, Volume: 20, Issue:115

    Topics: Anticholesteremic Agents; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2011
The JUPITER trial: myth or reality?
    Current atherosclerosis reports, 2011, Volume: 13, Issue:5

    Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Outcome Assessment, Health Care; Patient Selection; Primary Prevention; Pyrimidines; Research Design; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; United States

2011
A tale of three labels: translating the JUPITER trial data into regulatory claims.
    Clinical trials (London, England), 2011, Volume: 8, Issue:4

    Topics: Aged; Aged, 80 and over; Canada; Cardiovascular Diseases; Drug and Narcotic Control; Drug Labeling; Europe; Female; Fluorobenzenes; Government Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Translational Research, Biomedical; United States; United States Food and Drug Administration

2011
A tale of five opinions (at least).
    Clinical trials (London, England), 2011, Volume: 8, Issue:4

    Topics: Cardiovascular Diseases; Drug and Narcotic Control; Drug Labeling; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2011
Regulatory divergence.
    Clinical trials (London, England), 2011, Volume: 8, Issue:4

    Topics: Cardiovascular Diseases; Drug and Narcotic Control; Drug Labeling; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2011
Translating study results to labeling.
    Clinical trials (London, England), 2011, Volume: 8, Issue:4

    Topics: Cardiovascular Diseases; Drug and Narcotic Control; Drug Labeling; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2011
Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study.
    Lancet (London, England), 2011, Aug-20, Volume: 378, Issue:9792

    Topics: Aged; Aged, 80 and over; C-Reactive Protein; Calcium; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Survival Analysis; Tomography, X-Ray Computed

2011
[Extrapolating the NNT jeopardises biostatistics and leads to immortality].
    Atencion primaria, 2012, Volume: 44, Issue:5

    Topics: Biostatistics; Cardiovascular Diseases; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Numbers Needed To Treat; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2012
Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
    Journal of medical economics, 2012, Volume: 15, Issue:1

    Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Monte Carlo Method; Morbidity; Outcome Assessment, Health Care; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Sweden

2012
Extreme all-cause mortality in JUPITER requires reexamination of vital records.
    Cardiology, 2011, Volume: 120, Issue:2

    Topics: Aged; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Diabetic Angiopathies; Early Termination of Clinical Trials; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides

2011
Is chronic severe anemia an independent predictor of poor outcomes?
    Cardiology, 2011, Volume: 120, Issue:2

    Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2011
Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
    Current medical research and opinion, 2012, Volume: 28, Issue:3

    Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Smoking; Sulfonamides; Treatment Outcome; Triglycerides; United Kingdom

2012
Therapeutic options for statin-intolerant patients.
    Current medical research and opinion, 2012, Volume: 28, Issue:3

    Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2012
Increased mortality rates in the JUPITER trial.
    Cardiology, 2011, Volume: 120, Issue:4

    Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Sulfonamides

2011
Lipoprotein-associated phospholipase A₂ measurements: mass, activity, but little productivity.
    Clinical chemistry, 2012, Volume: 58, Issue:5

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2012
Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
    Clinical chemistry, 2012, Volume: 58, Issue:5

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Primary Prevention; Prospective Studies; Pyrimidines; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Sulfonamides

2012
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an inte
    Journal of the American College of Cardiology, 2012, Apr-24, Volume: 59, Issue:17

    Topics: Aged; Apolipoproteins B; Blood Chemical Analysis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Pyrimidines; Reference Values; Risk Assessment; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Treatment Outcome; Triglycerides; United States

2012
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2011, Volume: 76, Issue:4

    Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2011
Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease.
    International journal of cardiology, 2012, Jun-28, Volume: 158, Issue:1

    Topics: Cardiovascular Diseases; Clopidogrel; Coronary Disease; Drug Interactions; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ticlopidine

2012
Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model.
    Journal of medical economics, 2012, Volume: 15, Issue:6

    Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Computer Simulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides

2012
Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Pharmacotherapy, 2012, Volume: 32, Issue:7

    Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Netherlands; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2012
Statins: the good, the bad and the ugly.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2012, Jul-10, Volume: 184, Issue:10

    Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pneumonia; Pyrimidines; Sulfonamides

2012
Into the wardrobe of Narnia: beyond HIV infection a world of cardiovascular risk.
    BMJ case reports, 2012, Jul-17, Volume: 2012

    Topics: Acromegaly; Adenoma; Adult; Azetidines; Cardiovascular Diseases; Coinfection; Ezetimibe; Female; Fluorobenzenes; Hepatitis C; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Magnetic Resonance Imaging; Pituitary Neoplasms; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2012
Balancing the cardiometabolic benefits and risks of statins.
    Lancet (London, England), 2012, Aug-11, Volume: 380, Issue:9841

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2012
Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
    Journal of cardiology, 2012, Volume: 60, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Electrocardiography; Fluorobenzenes; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lipoproteins, HDL; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors

2012
Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
    Journal of medical economics, 2012, Volume: 15 Suppl 1

    Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Primary Prevention; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Spain; Sulfonamides

2012
I am a 60-year-old woman with CAD. My LDL is 64 and my HDL is 72 on Zocor, but my doctor thinks Crestor may be better for me. He says it is more potent and could reduce my numbers even more. I would have to pay for this drug out-of-pocket. Do you thin
    Heart advisor, 2011, Volume: 14, Issue:10

    Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2011
Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV.
    Arquivos brasileiros de cardiologia, 2012, Volume: 99, Issue:5

    Topics: Adult; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Female; Fibric Acids; Fluorobenzenes; HIV Infections; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides; Treatment Outcome; Triglycerides

2012
Statins induce hyperglycaemia of uncertain importance.
    Evidence-based medicine, 2013, Volume: 18, Issue:4

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Sulfonamides

2013
Conflict of interest: will it ever end?
    Internal medicine journal, 2012, Volume: 42, Issue:11

    Topics: Adenosine; Cardiovascular Diseases; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Clinical Trials, Phase III as Topic; Conflict of Interest; Drug Industry; Early Termination of Clinical Trials; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Motivation; Multicenter Studies as Topic; Periodicals as Topic; Platelet Aggregation Inhibitors; Pyrimidines; Reproducibility of Results; Research Support as Topic; Rosuvastatin Calcium; Sulfonamides; Ticagrelor; Truth Disclosure

2012
Statin therapy: rationale for a new agent, rosuvastatin.
    International journal of clinical practice, 2002, Volume: 56, Issue:5

    Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Female; Fluorobenzenes; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2002
52nd Annual Scientific Session of the American College of Cardiology, Chicago, March 30-April 2, 2003.
    International journal of clinical practice, 2003, Volume: 57, Issue:4

    Topics: Anticoagulants; Azetidines; Benzylamines; Cardiology; Cardiovascular Diseases; Chicago; Clinical Trials as Topic; Ezetimibe; Fluorobenzenes; Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2003
Using Crestor--and all statins--safely. Some simple steps can help minimize or avoid muscle problems from these cholesterol-lowering drugs.
    Harvard heart letter : from Harvard Medical School, 2005, Volume: 16, Issue:1

    Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pain; Pyridines; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2005
A projection of the impact of lipid-lowering therapy on high-risk employee disability and medical costs.
    Journal of occupational and environmental medicine, 2006, Volume: 48, Issue:10

    Topics: Cardiovascular Diseases; Cost Savings; Cost-Benefit Analysis; Fluorobenzenes; Forecasting; Health Care Costs; Humans; Hypolipidemic Agents; Insurance, Major Medical; Markov Chains; Models, Econometric; Pyrimidines; Rosuvastatin Calcium; Sick Leave; Sulfonamides

2006
Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
    Clinical therapeutics, 2006, Volume: 28, Issue:9

    Topics: Adult; Aged; Cardiovascular Diseases; Costs and Cost Analysis; Female; Fluorobenzenes; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Managed Care Programs; Medicare; Middle Aged; Models, Economic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States

2006
Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:12

    Topics: Adult; Antipsychotic Agents; Cardiovascular Diseases; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Psychotic Disorders; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Schizophrenia; Sulfonamides; Treatment Outcome

2006
Use of high-sensitivity CRP to predict first cardiovascular events.
    Lancet (London, England), 2007, Apr-14, Volume: 369, Issue:9569

    Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2007
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
    Vascular pharmacology, 2008, Volume: 48, Issue:1

    Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol; Coronary Vessels; Diabetes Mellitus, Type 2; Enalapril; Endothelium, Vascular; Fatty Acids; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesenteric Arteries; Metabolic Syndrome; Oxidative Stress; Pyrimidines; Rats; Rats, Zucker; Rosuvastatin Calcium; Sulfonamides; Triglycerides

2008
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:5

    Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States

2008
[Statin therapy for systolic heart failure. The CORONA trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)].
    Der Internist, 2008, Volume: 49, Issue:7

    Topics: Aged; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Female; Fluorobenzenes; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Proportional Hazards Models; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides; Systole; Treatment Outcome

2008
The comparative effectiveness of rosuvastatin vs. other statins in patients with an increased risk of failure to reach NCEP ATP III goal.
    International journal of clinical practice, 2008, Volume: 62, Issue:6

    Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2008